Slightly Alive — Improving Antituberculosis Therapy
New England Journal of Medicine · 2026-11-19
DOI: 10.1056/nejme2614653 ↗At a glance
Journal article in New England Journal of Medicine, published online on 2026-11-19. Written by Eric J. Rubin. 6 references.
Abstract (original language)
Tuberculosis is an ancient scourge that remains a modern challenge. Despite the availability of good treatment for drug-susceptible disease, an enormous number of deaths still occur worldwide. Although there are many reasons for this disparity, two are related to our current standard four-drug regimen for drug-susceptible pulmonary tuberculosis (isoniazid, rifampin, ethambutol, and pyrazinamide): the duration of treatment is quite long, which makes adherence challenging, and the effectiveness is poor in patients infected with multidrug-resistant organisms. Although antibiotic development has been deprioritized by many organizations, research involving drugs for tuberculosis has remained a bright spot, and many new antituberculosis agents are . . .
Cite
APA
Rubin, E. J. (2026). Slightly Alive — Improving Antituberculosis Therapy. New England Journal of Medicine. https://doi.org/10.1056/nejme2614653
Vancouver
Rubin EJ. Slightly Alive — Improving Antituberculosis Therapy. New England Journal of Medicine. 2026. doi:10.1056/nejme2614653
BibTeX
@article{Rubin2026,
author = {Rubin, Eric J.},
title = {Slightly Alive — Improving Antituberculosis Therapy},
journal = {New England Journal of Medicine},
year = {2026},
doi = {10.1056/nejme2614653}
}
EUVIMED